Theravance Biopharma, Inc. (TBPH)

Price$16.29

Value ScoreB

Growth ScoreB

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)-27.68%

Price vs S&P 500 (4W)-4.22%

VGM Score68.11

Market Capitalization$839.80M

P/E Ratio (Annual)7.93x

All Metrics

P/CF (Annual)3.52x

Book Value / Share (Quarterly)$5.64

P/TBV (Annual)1.18x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)27.95%

Cash Flow / Share (Quarterly)$5.22

Price vs S&P 500 (YTD)-21.09%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)104.34%

EPS (TTM)$2.20

10-Day Avg Trading Volume0.41M

EPS Excl Extra (TTM)$2.20

Revenue Growth (5Y)8.37%

EPS (Annual)$2.06

ROI (Annual)32.14%

Gross Margin (Annual)100.00%

Net Profit Margin (5Y Avg)250.84%

Cash / Share (Quarterly)$7.66

P/E Basic Excl Extra (TTM)7.33x

Revenue Growth QoQ (YoY)15.02%

P/E Normalized (Annual)7.93x

ROA (Last FY)21.81%

Revenue Growth TTM (YoY)68.20%

EBITD / Share (TTM)$1.02

ROE (5Y Avg)-14.54%

Operating Margin (TTM)46.78%

Cash Flow / Share (Annual)$4.67

P/B Ratio2.89x

P/B Ratio (Quarterly)2.88x

Net Income / Employee (Annual)$1,176,600

EV / Revenue (TTM)5.32x

Net Interest Coverage (TTM)-34.84x

ROA (TTM)25.46%

EV / EBITDA (TTM)11.04x

EPS Incl Extra (Annual)$2.06

Current Ratio (Annual)10.93x

Quick Ratio (Quarterly)12.91x

3-Month Avg Trading Volume0.55M

52-Week Price Return51.25%

EV / Free Cash Flow (Annual)2.45x

P/E Incl Extra (TTM)7.33x

Revenue / Employee (TTM)$1,219,700

Tangible BV / Share (Quarterly)$4.84

P/S Ratio (Annual)7.81x

Asset Turnover (Annual)0.22x

52-Week High$21.03

Operating Margin (5Y Avg)-155.74%

EPS Excl Extra (Annual)$2.06

CapEx CAGR (5Y)-63.65%

Tangible BV CAGR (5Y)30.85%

26-Week Price Return-19.75%

Quick Ratio (Annual)10.73x

13-Week Price Return19.96%

Total Debt / Equity (Annual)0.11x

Current Ratio (Quarterly)13.14x

Enterprise Value$584.49M

Revenue / Share Growth (5Y)12.57%

Asset Turnover (TTM)0.24x

Book Value / Share Growth (5Y)-2.62%

Revenue / Employee (Annual)$1,194,000

Inventory Turnover (Annual)0.08x

Pretax Margin (Annual)120.27%

Cash / Share (Annual)$6.18

3-Month Return Std Dev25.35%

Gross Margin (5Y Avg)88.64%

Net Income / Employee (TTM)$1,272,700

ROE (Last FY)35.69%

Net Interest Coverage (Annual)-2.11x

EPS Basic Excl Extra (Annual)$2.06

P/FCF (TTM)2.99x

Receivables Turnover (TTM)7.10x

EV / Free Cash Flow (TTM)2.17x

Total Debt / Equity (Quarterly)0.11x

EPS Incl Extra (TTM)$2.20

Receivables Turnover (Annual)3.36x

ROI (TTM)39.02%

P/S Ratio (TTM)7.65x

Pretax Margin (5Y Avg)-139.06%

Revenue / Share (Annual)$2.09

Tangible BV / Share (Annual)$6.77

Forward P/E13.45x

Price vs S&P 500 (52W)26.89%

P/E Ratio (TTM)7.33x

Year-to-Date Return-12.93%

5-Day Price Return2.20%

EPS Normalized (Annual)$2.06

ROA (5Y Avg)16.36%

Net Profit Margin (Annual)98.54%

Month-to-Date Return1.43%

Cash Flow / Share (TTM)$-0.98

EBITD / Share (Annual)$0.93

EPS Growth (3Y)-44.23%

Operating Margin (Annual)43.18%

LT Debt / Equity (Annual)0.11x

P/CF (TTM)3.12x

ROI (5Y Avg)19.00%

P/E Excl Extra (TTM)7.33x

LT Debt / Equity (Quarterly)0.11x

EPS Basic Excl Extra (TTM)$2.20

P/TBV (Quarterly)2.12x

P/B Ratio (Annual)3.20x

Inventory Turnover (TTM)0.08x

Pretax Margin (TTM)124.72%

Book Value / Share (Annual)$5.81

Price vs S&P 500 (13W)11.70%

Beta0.20x

P/FCF (Annual)3.52x

Revenue / Share (TTM)$2.14

ROE (TTM)43.85%

52-Week Low$10.42

vGradeB

gGradeB

mGradeB

vgmGradeB

Show chart for

Earnings Surprise History

Q1 26-0.03est. -0.15

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.08

3.85

3.92

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
TBPHTheravance Biopharma, Inc.	B	B	B	$16.29
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Theravance Biopharma is a biopharmaceutical company developing organ-selective small-molecule medicines for inflammation and immunology, with a focus on lung-selective drugs for respiratory disease. The company's approach aims to improve the therapeutic index by maximizing efficacy while minimizing systemic side effects. Its portfolio includes YUPELRI (revefenacin), an FDA-approved inhalation solution for COPD maintenance treatment.